| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
||
|
||
| |
||
| |
|
|
|
||
Cholinesterase Inhibitors
Recent Studies and Reviews on CHEIs
Comprehensive Reviews
1. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr. 2002;14 Suppl 1:93-126
2. Grossberg GT. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr. 2002;14 Suppl 1:27-49.
3. Potkin SG. The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Int Psychogeriatr. 2002;14 Suppl 1:7-26.
4. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):131-45.
Galantamine
1. Wilcock G, Howe I, Coles H, Lilienfeld S et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20(10):777-89.
2. Migliaccio-Walle K, Getsios D, Caro JJ et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther. 2003 Jun;25(6):1806-25.
3. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002 Apr 13;359(9314):1283-90.
4. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. M. Raskind, and L. Truyen. Poster presented at the 15th Annual Meeting of the American Association for Geriatric Psychiatry, Orlando, Florida, February 24–27, 2002.
5. Winblad B. Maintaining functional and behavioral abilities in Alzheimer disease. Alzheimer Dis Assoc Disord. 2001 Aug;15 Suppl 1:S34-40.
6. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001 Feb 1;49(3):289-99.
7. Ferris SH. Switching previous therapies for Alzheimer's disease to galantamine.Clin Ther. 2001;23 Suppl A:A3-7.
8. Rasmusen L, Yan B, Robillard A, Dunbar F. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther. 2001;23 Suppl A:A25-30.
9. Getsios D, Caro JJ, Caro G, Ishak K. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology. 2001 Sep 25;57(6):972-8.
10. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Mar-Apr;12(2):69-77.
Donepezil
1. Wilcock G, Howe I, Coles H et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20(10):777-89.
2. Gray R. Comparative study of donepezil and rivastigmine. Int J Clin Pract. 2003 Jun;57(5):449
3 Geldmacher DS, Provenzano G, McRae T et al. Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease. J Am Geriatr Soc. 2003 Jul;51(7):937-944.
4. Feldman H, Gauthier S, Hecker J et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc. 2003 Jun;51(6):737-44.
5. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract. 2002 Jul-Aug;56(6):441-6.
6. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001 Dec;49(12):1590-9.
7. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001 Aug 28;57(4):613-20.
8. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 Aug 14;57(3):489-95.
9. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14;57(3):481-8.
Rivastigmine
1. Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther. 2003 Jun;25(6):1634-53.
2. Farlow M, Potkin S, Koumaras B et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol. 2003 Jun;60(6):843-8.
3. Gray R. Comparative study of donepezil and rivastigmine. Int J Clin Pract. 2003 Jun;57(5):449
4. Weiser M, Rotmensch HH, Korczyn AD, Hartman R, Cicin-Sain A, Anand R. A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int J Geriatr Psychiatry. 2002 Apr;17(4):343-6.
5.Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13(3):183-92.
6. Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract. 2002 Apr;56(3):206-14. Review.
7. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001 Mar;58(3):417-22.
8. Bilikiewicz A, Opala G, Podemski R, Puzynski S, Lapin J, Soltys K, Ochudlo S, Barcikowska M, Pfeffer A, Bilinska M, Paradowski B, Parnowski T, Gabryelewicz T. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. Med Sci Monit. 2002 Feb;8(2):PI9-15.